A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Solid Tumors (Master Protocol)
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Damian Silvia
Main Facility: Oncologia Medica 1
Drug: Precemtabart Tocentecan (M9140)
Pathologies: Pancreatic cancer, Lung cancer, Stomach tumors
ClinicalTrials.gov: Read the details about clinical trials
Study aims to investigate the clinical activity of precemtabart tocentecan (M9140), an antibody-drug conjugate specific to carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) in adults multiple tumor types which express CEACAM5.
Last update: 21/04/2026